Nesiritide Treatment of Noncardiogenic Pulmonary Edema

Bobadilla, Rodel V; Oppelt, Thomas F; Hirshy, Thadd C

doi:10.1345/aph.1c331

Cited by 7 publications

(4 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…52 Conversely, causes of non-cardiogenic pulmonary oedema can cause elevated BNP levels. 53 It is thought that this represents a response to cardiac damage caused by intense neurohumoral activation rather than de novo synthesis of BNP in the central nervous system.…”

Section: And Possibly Agents That Increase the Availability Of Endogementioning

confidence: 99%

Utility of Brain Natriuretic Peptide (BNP) Measurement in Cardiovascular Disease

Sullivan

West

Jeremy

2005

Heart, Lung and Circulation

View full text Add to dashboard Cite

Section: And Possibly Agents That Increase the Availability Of Endogementioning

confidence: 99%

Utility of Brain Natriuretic Peptide (BNP) Measurement in Cardiovascular Disease

Sullivan

West

Jeremy

2005

Heart, Lung and Circulation

View full text Add to dashboard Cite

“…In another study, nesiritide was begun after diuretic therapy failed to relieve pulmonary edema adequately after 12 hours. 9 In our two patients, we used nesiritide and diuretics together as initial therapy in an effort to achieve improved diuresis rather than giving diuretics alone. In both patients, significant diuresis and weight loss occurred with simultaneous administration of both drugs.…”

Section: Discussionmentioning

confidence: 99%

“…Also of interest, in a recent case report, urine output increased from 3.4 L after 24 hours to more than 13 L within 2 days after the start of nesiritide therapy. 9 Furosemide was given for diuresis during the first 24 hours to treat noncardiogenic pulmonary edema; nesiritide was added over the next 48 hours.…”

mentioning

confidence: 99%

Nesiritide for Treatment of Heart Failure Due to Right Ventricular Dysfunction

et al. 2004

View full text Add to dashboard Cite

Little information exists regarding the use of nesiritide for treatment of right-sided heart failure. Similarly, little information is available regarding routine use of combination nesiritide and diuretics as initial therapy to relieve edema due to heart failure. Nesiritide may be beneficial in combination with diuretics because it reduces activity of the renin-angiotensin-aldosterone system. It is unclear how potent nesiritide is as a diuretic. Patients exhibit wide variability in clinical response from the diuretic effects of the drug. Two patients were given a combination of nesiritide and diuretics as initial treatment of right-sided heart failure; both experienced significant diuresis and weight loss. Further literature is needed to clarify the role of nesiritide in the treatment of right-sided heart failure.

show abstract

“…Nesiritide also appears to be effective and well tolerated in patients receiving concomitant β-blocker therapy and in HF patients with ACS and renal insufficiency [88,90]. ANP/BNP might also prove useful as an adjunctive therapy to percutaneous coronary intervention for acute MI [91] and in the treatment of post-operative cardiac patients [92], noncardiogenic acute pulmonary oedema [93], cor pulmonale [94] and acute renal failure [95]. A preliminary report of BNP use in paediatric care suggests the agent is also safe and effective in this population [96].…”

Section: Nesiritidementioning

confidence: 99%

Cardiac natriuretic peptides for cardiac health

Rademaker¹,

Richards²

2004

Clinical Science

View full text Add to dashboard Cite

The cardiac natriuretic peptides, ANP (atrial natriuretic peptide) and BNP (brain natriuretic peptide), are secreted by the heart in proportion to cardiac transmural pressures. They possess a wide range of effects in multiple tissues facilitating overall pressure/volume homoeostasis. The close relationship between plasma concentrations of these peptides and 'cardiac load' has led to their use as biomarkers of cardiac health with diagnostic and prognostic applications in a variety of disorders affecting the cardiovascular system. BNP and its N-terminal fragment (NT-BNP) are especially sensitive indicators of cardiac dysfunction and remodelling, and correlate strongly with severity. Given that cardiac ischaemia is also an important trigger for the release of these ventricular peptides, they may likewise play a role in the detection of coronary artery disease. Measurement of BNP/NT-BNP shows particular promise as a 'rule out' test for suspected cases of HF (heart failure) in both emergency care and outpatient settings, and may assist in identifying individuals with asymptomatic ventricular impairment who will benefit from therapy preventing progression to overt HF. The BNP peptides also predict subsequent haemodynamic deterioration and adverse events in cardiovascular disease, and can therefore be used to monitor those at high risk and act as a guide to optimization of treatment. The favourable biological properties of the natriuretic peptides have also led to their use as therapeutic agents.

show abstract

Nesiritide Treatment of Noncardiogenic Pulmonary Edema

Abstract: Nesiritide appears to be an efficacious treatment for acute pulmonary edema, resistant to standard-of-care therapies, in the presence of normal left-ventricular function.

Cited by 7 publications

References 3 publications

Utility of Brain Natriuretic Peptide (BNP) Measurement in Cardiovascular Disease

Utility of Brain Natriuretic Peptide (BNP) Measurement in Cardiovascular Disease

Nesiritide for Treatment of Heart Failure Due to Right Ventricular Dysfunction

Cardiac natriuretic peptides for cardiac health

Contact Info

Product

Resources

About